<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01162486</url>
  </required_header>
  <id_info>
    <org_study_id>CDC-NCHHSTP-5779</org_study_id>
    <nct_id>NCT01162486</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers</brief_title>
  <acronym>TBTC S29B</acronym>
  <official_title>Phase I Dose Escalation Study of the Pharmacokinetics, Safety and Tolerability of Rifapentine and the Effects of Increasing Doses of Rifapentine on Induction of Metabolizing Enzymes in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate (1) the safety and tolerability of escalating doses of
      rifapentine (RPT) administered daily by oral; (2) the effect of increasing doses of RPT on
      cytochrome P450 isoform 3A (CYP3A) enzyme metabolizing activity, using single-dose midazolam
      (MDZ); and (3) the effect of increasing doses of RPT on autoinduction of RPT metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      On day 1, volunteers will receive a single dose of MDZ dosed at 15 mg delivered orally, and a
      24-hour PK analysis of MDZ and its metabolite, 1-OH-midazolam (1-OH-MDZ) will be performed.
      RPT (or RIF) will be given as a single daily dose (5, 10, 15, or 20 mg/kg, depending on the
      dose cohort) on days 2-15 (14 doses). A 24-hour PK analysis of RPT (or RIF) and its
      25-deacetyl metabolite (25-des-RPT) will be performed after the first dose (day 2). On day
      15, volunteers receive a second single dose of MDZ. A 72-hour RPT (or RIF) and 24-hour MDZ
      (and 1-OH-MDZ) PK analysis will be performed after the second dose of MDZ beginning on day
      15. The PK sampling will occur both on an in-patient basis in the General Clinical Research
      Center (GCRC) and on an out-patient basis in the study clinic. Volunteers will undergo
      assessments for adverse events (AEs) several times throughout the study.

      Each dose cohort will contain 6 subjects. RPT dosing will begin at 5 mg/kg (6 volunteers) and
      increase by 5 mg/kg increments (6 volunteers each at 10, 15, and 20 mg/kg) to a maximum dose
      of 20 mg/kg unless dose-limiting toxicities (DLT) are seen in two or more patients within a
      dose cohort, in which case a dose that is 2.5 mg/kg lower than the previous dose will be
      enrolled to determine the maximal tolerated dose (MTD). In addition, one cohort of 6 subjects
      will receive RIF at 10 mg/kg daily, rather than RPT, as a comparator arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Grade 2 or Higher Adverse Events Over the Course of the 26 Day Trial</measure>
    <time_frame>26 days</time_frame>
    <description>Number of Participants with Grade 2 or higher adverse events over 26 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC of RPT Over 24 Hours Post-dose)</measure>
    <time_frame>days: 2, 15</time_frame>
    <description>To determine and compare the steady-state pharmacokinetics and dose linearity of escalating daily doses of rifapentine in dose cohorts of 5 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg in healthy volunteers after a single dose (Day 2) or multiple doses (Day 15)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Midazolam, AUC Over 12 Hours Post-dose</measure>
    <time_frame>days: 1, 15</time_frame>
    <description>To compare and describe, the pharmacokinetics of single-dose midazolam alone (Day 1) versus midazolam co-administered with either steady-state rifapentine at multiple daily doses (5, 10, 15, and 20 mg/kg) or rifampin at 10 mg/kg daily (Day 15)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transporter Genes</measure>
    <time_frame>day 3</time_frame>
    <description>To determine the effects of polymorphisms of transporter genes on rifampin and rifapentine PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rifapentine Concentrations From Dried Blood Spots</measure>
    <time_frame>days 2, 3, 7, 10, 15, 16, 17, 18</time_frame>
    <description>To develop methods for determination of rifapentine concentrations from dried blood spots on sampling paper</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Rifampin control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifampin + midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 1 - 5 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 2 - 10 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 3 - 15 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 4 - 20 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RPT 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RPT Cohort 5 - Maximal tolerated dose, if dose limiting toxicities are observed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampin &amp; midazolam</intervention_name>
    <description>rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>Rifampin control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine &amp; midazolam</intervention_name>
    <description>rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine &amp; midazolam</intervention_name>
    <description>rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine &amp; midazolam</intervention_name>
    <description>rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine and midazolam</intervention_name>
    <description>rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifapentine and midazolam</intervention_name>
    <description>rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
    <arm_group_label>RPT 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ability and willingness to provide written informed consent.

          2. Age greater than or equal to 18 years, and less than or equal to 65 years.

          3. Weight of 50-100 kg for enrollment into the RPT cohorts

          4. Weight of 50-80 kg for enrollment into the RIF cohort

          5. Within 28 or fewer days prior to enrollment, a complete blood count with differential,
             comprehensive serum chemistry profile, HIV antibody test, and Hepatitis C antibody
             test will be performed, with the following laboratory values:

               1. Serum amino aspartate transferase (AST) less than the upper limit of normal

               2. Total bilirubin level less than the upper limit of normal

               3. Serum creatinine &lt;1.5 mg/dL

               4. Hemoglobin greater than 12.0 for men, greater than 11.0 for women

               5. Platelet count greater than or equal to 125,000 /cu mm

               6. Absolute neutrophil count greater than or equal to 1250 /cu mm

               7. Serum albumin greater than 3.5 g/dL

               8. HIV antibody test negative

               9. Hepatitis C antibody negative

          6. For women of childbearing potential, a negative serum bHCG pregnancy test, performed
             at screening.

          7. During the study and for 14 days after the last dose of study medication, women of
             childbearing potential must agree to practice barrier contraception for the duration
             of the study.

        Exclusion Criteria:

          1. Pregnant or breastfeeding

          2. Known intolerance of or allergy to rifamycins

          3. Allergy to benzodiazepines

          4. Use of rifamycin antibiotics in the 30 days prior to enrollment

          5. Inability to take oral medications

          6. Renal, hepatic, cardiac (except benign heart murmur), or endocrine disorder; or
             malignancy; or immunocompromise.

          7. History of any acute or chronic illness that requires current medical therapy.

          8. Prior gastrointestinal surgery involving stomach, biliary system, pancreas, or small
             intestine.

          9. Any medical condition that, in the opinion of the investigator, would interfere with
             the subject's ability to participate in the protocol.

         10. Any illicit drug use within the preceding 2 months. Subjects must agree to abstain
             from alcohol and illicit drug use during the study. Smokers must agree to abstain from
             cigarettes or to smoke fewer than 5 cigarettes per day.

         11. Current use of any prescription medication(s), including oral contraceptives.

         12. Planned use, during the study from Day 0 through the last PK blood draw, of any of the
             following: prescription medication(s), herbal supplement(s), vitamin(s), mineral
             supplement(s), over-the-counter medication(s), or grapefruit juice. Subjects must
             agree to abstain from grapefruit juice during the study.

         13. Participation in any other investigational drug study within 30 days prior to study
             entry and during study.

         14. Inability to participate in pharmacokinetic visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kelly Dooley, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan Dorman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins Univeristy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 13, 2010</study_first_submitted>
  <study_first_submitted_qc>July 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2010</study_first_posted>
  <results_first_submitted>November 20, 2014</results_first_submitted>
  <results_first_submitted_qc>January 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-infective agents</keyword>
  <keyword>Anti-bacterial agents</keyword>
  <keyword>Rifampin</keyword>
  <keyword>Rifapentine</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Molecular mechanisms of pharmacological action</keyword>
  <keyword>Antitubercular agents</keyword>
  <keyword>Pharmacologic actions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Rifapentine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rifampin Control</title>
          <description>Rifampin + midazolam
Rifampin &amp; midazolam: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="P2">
          <title>RPT 1</title>
          <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="P3">
          <title>RPT 2</title>
          <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="P4">
          <title>RPT 3</title>
          <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="P5">
          <title>RPT 4</title>
          <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Took at Least One Dose Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>low ANC</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>vomited Rifampin/ gagged with midazolam</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>elevated LFTs</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>4 of the enrolled participants did not get to start. Two withdrew their consent, one had a transaminase elevation and one was non-compliant. Only 33 (out of the 37 enrolled participants) were able to start the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Rifampin Control</title>
          <description>Rifampin + midazolam
Rifampin &amp; midazolam: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="B2">
          <title>RPT 1</title>
          <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="B3">
          <title>RPT 2</title>
          <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="B4">
          <title>RPT 3</title>
          <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="B5">
          <title>RPT 4</title>
          <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="7"/>
            <count group_id="B5" value="8"/>
            <count group_id="B6" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" lower_limit="25" upper_limit="50"/>
                    <measurement group_id="B2" value="50" lower_limit="29" upper_limit="55"/>
                    <measurement group_id="B3" value="44" lower_limit="27" upper_limit="58"/>
                    <measurement group_id="B4" value="41" lower_limit="23" upper_limit="59"/>
                    <measurement group_id="B5" value="47" lower_limit="30" upper_limit="55"/>
                    <measurement group_id="B6" value="44" lower_limit="23" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 2 or Higher Adverse Events Over the Course of the 26 Day Trial</title>
        <description>Number of Participants with Grade 2 or higher adverse events over 26 days</description>
        <time_frame>26 days</time_frame>
        <population>Four withdrew prior to receiving study rifamycin so were not included in the safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Rifampin Control</title>
            <description>Rifampin + midazolam
Rifampin &amp; midazolam: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O2">
            <title>RPT 1</title>
            <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O3">
            <title>RPT 2</title>
            <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O4">
            <title>RPT 3</title>
            <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O5">
            <title>RPT 4</title>
            <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 2 or Higher Adverse Events Over the Course of the 26 Day Trial</title>
          <description>Number of Participants with Grade 2 or higher adverse events over 26 days</description>
          <population>Four withdrew prior to receiving study rifamycin so were not included in the safety population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (AUC of RPT Over 24 Hours Post-dose)</title>
        <description>To determine and compare the steady-state pharmacokinetics and dose linearity of escalating daily doses of rifapentine in dose cohorts of 5 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg in healthy volunteers after a single dose (Day 2) or multiple doses (Day 15)</description>
        <time_frame>days: 2, 15</time_frame>
        <population>These patients completed PK visits on Day 2 and 15 (Three participants in this non-control group - subdivided into 4- did not complete the study). Reasons provided in the participant flow session</population>
        <group_list>
          <group group_id="O1">
            <title>RPT 1</title>
            <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O2">
            <title>RPT 2</title>
            <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O3">
            <title>RPT 3</title>
            <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O4">
            <title>RPT 4</title>
            <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (AUC of RPT Over 24 Hours Post-dose)</title>
          <description>To determine and compare the steady-state pharmacokinetics and dose linearity of escalating daily doses of rifapentine in dose cohorts of 5 mg/kg, 10 mg/kg, 15 mg/kg and 20 mg/kg in healthy volunteers after a single dose (Day 2) or multiple doses (Day 15)</description>
          <population>These patients completed PK visits on Day 2 and 15 (Three participants in this non-control group - subdivided into 4- did not complete the study). Reasons provided in the participant flow session</population>
          <units>(mcg*h/ml)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RPT AUC, Day 2 single dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="101" upper_limit="157"/>
                    <measurement group_id="O2" value="242" lower_limit="231" upper_limit="260"/>
                    <measurement group_id="O3" value="363" lower_limit="310" upper_limit="430"/>
                    <measurement group_id="O4" value="403" lower_limit="357" upper_limit="452"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RPT AUC, Day 15 multiple dose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="142" upper_limit="251"/>
                    <measurement group_id="O2" value="330" lower_limit="284" upper_limit="340"/>
                    <measurement group_id="O3" value="560" lower_limit="401" upper_limit="735"/>
                    <measurement group_id="O4" value="483" lower_limit="414" upper_limit="546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Midazolam, AUC Over 12 Hours Post-dose</title>
        <description>To compare and describe, the pharmacokinetics of single-dose midazolam alone (Day 1) versus midazolam co-administered with either steady-state rifapentine at multiple daily doses (5, 10, 15, and 20 mg/kg) or rifampin at 10 mg/kg daily (Day 15)</description>
        <time_frame>days: 1, 15</time_frame>
        <population>29 participants completed both midazolam PK visits; one person in RPT1 visit was not analyzed because his samples were zero and was found to have been non-compliant with regimen</population>
        <group_list>
          <group group_id="O1">
            <title>Rifampin Control</title>
            <description>Rifampin + midazolam
Rifampin &amp; midazolam: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O2">
            <title>RPT 1</title>
            <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O3">
            <title>RPT 2</title>
            <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O4">
            <title>RPT 3</title>
            <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O5">
            <title>RPT 4</title>
            <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Midazolam, AUC Over 12 Hours Post-dose</title>
          <description>To compare and describe, the pharmacokinetics of single-dose midazolam alone (Day 1) versus midazolam co-administered with either steady-state rifapentine at multiple daily doses (5, 10, 15, and 20 mg/kg) or rifampin at 10 mg/kg daily (Day 15)</description>
          <population>29 participants completed both midazolam PK visits; one person in RPT1 visit was not analyzed because his samples were zero and was found to have been non-compliant with regimen</population>
          <units>ng*h/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC 0-12 Midazolam alone (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="116" upper_limit="197"/>
                    <measurement group_id="O2" value="150" lower_limit="108" upper_limit="238"/>
                    <measurement group_id="O3" value="114" lower_limit="111" upper_limit="128"/>
                    <measurement group_id="O4" value="204" lower_limit="158" upper_limit="255"/>
                    <measurement group_id="O5" value="173" lower_limit="118" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC 0-12 Midazolam with RIF (Day 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.9" lower_limit="10.0" upper_limit="55.8"/>
                    <measurement group_id="O2" value="14.2" lower_limit="7.34" upper_limit="20.1"/>
                    <measurement group_id="O3" value="10.2" lower_limit="10.0" upper_limit="10.4"/>
                    <measurement group_id="O4" value="14.0" lower_limit="12.6" upper_limit="15.2"/>
                    <measurement group_id="O5" value="11.7" lower_limit="8.8" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transporter Genes</title>
        <description>To determine the effects of polymorphisms of transporter genes on rifampin and rifapentine PK parameters</description>
        <time_frame>day 3</time_frame>
        <population>This outcome was not assessed because data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Rifampin Control</title>
            <description>Rifampin + midazolam
Rifampin &amp; midazolam: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O2">
            <title>RPT 1</title>
            <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O3">
            <title>RPT 2</title>
            <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O4">
            <title>RPT 3</title>
            <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O5">
            <title>RPT 4</title>
            <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Transporter Genes</title>
          <description>To determine the effects of polymorphisms of transporter genes on rifampin and rifapentine PK parameters</description>
          <population>This outcome was not assessed because data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rifapentine Concentrations From Dried Blood Spots</title>
        <description>To develop methods for determination of rifapentine concentrations from dried blood spots on sampling paper</description>
        <time_frame>days 2, 3, 7, 10, 15, 16, 17, 18</time_frame>
        <population>This outcome was not assessed because data was not collected</population>
        <group_list>
          <group group_id="O1">
            <title>Rifampin Control</title>
            <description>Rifampin + midazolam
Rifampin &amp; midazolam: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O2">
            <title>RPT 1</title>
            <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O3">
            <title>RPT 2</title>
            <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O4">
            <title>RPT 3</title>
            <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
          <group group_id="O5">
            <title>RPT 4</title>
            <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
          </group>
        </group_list>
        <measure>
          <title>Rifapentine Concentrations From Dried Blood Spots</title>
          <description>To develop methods for determination of rifapentine concentrations from dried blood spots on sampling paper</description>
          <population>This outcome was not assessed because data was not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rifampin Control</title>
          <description>Rifampin + midazolam
Rifampin &amp; midazolam: rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="E2">
          <title>RPT 1</title>
          <description>RPT Cohort 1 - 5 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 5 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="E3">
          <title>RPT 2</title>
          <description>RPT Cohort 2 - 10 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 10 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="E4">
          <title>RPT 3</title>
          <description>RPT Cohort 3 - 15 mg/kg
rifapentine &amp; midazolam: rifapentine - tablet, 15 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
        <group group_id="E5">
          <title>RPT 4</title>
          <description>RPT Cohort 4 - 20 mg/kg
rifapentine and midazolam: rifapentine - tablet, 20 mg/kg, daily 15 days midazolam – liquid syrup, 15 mg, days 1 and 15</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="7"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypertransaminasemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Kelly E. Dooley</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-955-3100</phone>
      <email>kdooley1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

